Pediatric Cancer Immunotherapy

Immunotherapy is a promising new treatment option for certain kinds of childhood cancers. Chimeric antigen receptor (CAR) T-cell therapy is a type of immunotherapy that uses your child’s own immune system to fight cancer.

Stanford Medicine Children’s Health combines cutting-edge immunotherapy research and an experienced team of compassionate doctors to provide the best immunotherapy treatments for children and young adults with cancer. From KYMRIAH, the first FDA-approved CAR T-cell therapy, to clinical trials available only at Stanford, we offer patients excellent care using the latest therapies.

Our care team includes world-renowned pediatric oncologists, led by Crystal Mackall, MD, who was part of a team at the National Institutes of Health that developed some of the earliest immunotherapy treatments. Our pediatric-specific research program helps us bring cures from the lab to your child without delay. Dr. Mackall also leads the Pediatric Cancer Immunotherapy Trials Network, where our experts continually collaborate with other doctors and researchers to bring your child the best possible care.

YouTube Play/Stop Button

The promise of cancer immunotherapy

Crystal Mackall, MD, an internationally recognized expert in cancer immunotherapy, discusses early progress in CAR-T cell therapy and says she’s optimistic that future research will continue to improve patient care.